Cory Y. McLean, PhD, with his sponsor Joseph F. Costello, PhD, at University of California, San Francisco, California, is interested in understanding how low-grade brain tumors change to become high-grade tumors. He is studying primary and recurrent brain tumors to identify the genetic and epigenetic alterations that differentiate tumors from normal tissue and cause tumor transformation from low- to high-grade. These studies may identify new targets for future drug development or indicate existing treatments that could be used to effectively treat low-grade tumors.
Katarina Moravcevic, PhD, with her sponsor Amita Sehgal, PhD, at University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, is studying sleep deprivation, which leads to an increased risk of several diseases including cancer. Little is currently known about the function of sleep or about the molecular mechanisms that control the need to sleep. To begin to understand why sleep deprivation has such a negative impact on human health, she will address how and why the need to sleep builds up after prolonged wakefulness.
Renee Otten, PhD, with his sponsor Dorothee Kern, PhD, at Brandeis University, Waltham, Massachusetts, is investigating the catalytic mechanism of protein kinases, an important family of proteins that are present in bacteria, plants and humans. These proteins play a central role in signal transduction pathways and orchestrating the cell cycle; aberrant activity, however, has been shown to cause certain human cancers. A firm grasp of their mechanism is thus of great interest because it holds promise for the development of new therapeutics.
Douglas H. Phanstiel, PhD, with his sponsor Michael P. Snyder, PhD, at Stanford University School of Medicine, Stanford, California, is studying transcription factors (TF), proteins that bind
|Contact: Yung S. Lie, PhD|
Damon Runyon Cancer Research Foundation